Drug · CHEMBL109
VALPROIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. VALPROIC ACID. Drugs and targets, record CHEMBL109. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL109
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 44089, Acide valproique, Acido valproico, NSC-93819, Pentanoic acid, 2-propyl, Valproate, Valproic acid extended release
- ChEMBL
- Open Targets' highest stage
- Approval, for 6 of its 103 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | Succinate semialdehyde dehydrogenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/7915 |
Source ChEMBL
Diseases103
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 103Source Open Targets
See all 103 diseasesTrials222
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00261443 | A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania | Phase 4 | 1,270 | 2011-04-27 | valproate | Its name | ClinicalTrials.gov |
| NCT00280566 | Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed) | Phase 3 | 584 | 2009-12-14 | valproate | Its name | ClinicalTrials.gov |
| NCT02600507 | Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression | Phase 3 | 529 | 2023-05-17 | valproate | Its name | ClinicalTrials.gov |
| NCT01960075 | Established Status Epilepticus Treatment Trial | Phase 3 | 478 | 2020-02-28 | valproic acid | Its name | ClinicalTrials.gov |
| NCT00088452 | Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study | Phase 3 | 453 | 2020-10-14 | valproic acid | Its name | ClinicalTrials.gov |
| NCT01267864 | Valproate Versus Ketorolac Versus Metoclopramide | Phase 4 | 330 | 2018-06-04 | valproate | Its name | ClinicalTrials.gov |
| NCT00071721 | Valproate in Dementia (VALID) | Phase 3 | 313 | 2010-10-20 | valproate | Its name | ClinicalTrials.gov |
| NCT01674010 | Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder | Phase 2 | 309 | 2015-10-12 | valproic acid | Its name | ClinicalTrials.gov |
| NCT00483548 | Adjunctive Ziprasidone in the Treatment of Bipolar I Depression | Phase 3 | 298 | 2010-02-23 | valproate | Its name | ClinicalTrials.gov |
| NCT00807989 | The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy | Phase 4 | 207 | 2015-05-29 | valproate | Its name | ClinicalTrials.gov |
1 to 10 of 222
See all 222 trialsComparisons in its trials44
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Valproate vs Placebo: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician | 25 of 153 | 29 of 160 | 313 | NCT00071721 | Trial comparisons |
| Valproate vs Placebo: serious adverse events | 51 of 153 | 62 of 160 | 313 | NCT00071721 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 1 of 147 | 6 of 147 | 294 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Response: Number of Subjects With Total MADRS Score Reduction ≥ 50 Percent From Baseline at Week 6 | 62 of 145 | 65 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: Clinical Global Impression - Improvement Scale (CGI-Improvement or CGI-I): Number of Subjects With Response (Much Improved or Very Much Improved) at Week 6 | 66 of 145 | 69 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Remission: Number of Subjects With Total MADRS Score ≤ 12 at Week 6 | 48 of 145 | 54 of 145 | 290 | NCT00483548 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: Retention Rate After 52 Weeks Maintenance Period | 104 of 104 | 98 of 98 | 202 | NCT00807989 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: serious adverse events | 9 of 104 | 0 of 98 | 202 | NCT00807989 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: Seizure Free Rate for 52 Weeks at Initial Target Dose | 43 of 90 | 50 of 78 | 168 | NCT00807989 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: Seizure Free Rate for 24 Weeks at Initial Target Dose | 51 of 90 | 59 of 78 | 168 | NCT00807989 | Trial comparisons |
1 to 10 of 44
See all 44 comparisons in its trialsPapers from its trials163
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Delayed Recall Module | 1 | 0 | ConductCognition |
| Selective Reminding Task | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL109
GET https://conductscience.org/api/drugs/v1/CHEMBL109/diseases?page=2